On the other hand, anti-PD-L1 treatment appeared to reduce human CD45+ immune cell infiltration in tumor xenografts, and this may be due to impairing the proliferation of PD-L1 expressing human immune cells including by antibody effector mechanisms, as previously described [56]. This evidence concerns the gene PTPRC and neoplasm.